Profile data is unavailable for this security.
About the company
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
- Revenue in CAD (TTM)0.00
- Net income in CAD-3.17m
- Incorporated2014
- Employees--
- LocationHemostemix IncSuite 730; 1015 - 4 St SWCALGARY T2R 1J4CanadaCAN
- Phone+1 (647) 919-8820
- Fax+1 (403) 818-7672
- Websitehttps://hemostemix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genix Pharmaceuticals Corp | 10.83k | -4.23m | 3.54m | -- | -- | -- | -- | 326.80 | -0.0714 | -0.0714 | 0.0002 | -0.0202 | 0.0049 | 0.0502 | 1.89 | -- | -191.99 | -54.69 | -476.20 | -68.59 | 23.08 | -- | -39,036.01 | -5,345.88 | 0.0541 | -10.33 | -- | -- | -- | -50.60 | -309.27 | -- | -- | -- |
| Eve & Co Inc | 7.77m | -5.92m | 3.76m | -- | -- | -- | -- | 0.4845 | -0.2055 | -0.2055 | 0.2698 | 0.733 | 0.1519 | 0.7493 | 8.73 | -- | -11.58 | -- | -24.24 | -- | -3.10 | -- | -76.22 | -- | 0.062 | -5.05 | 0.4892 | -- | 2.94 | -- | -71.97 | -- | -- | -- |
| Hemostemix Inc | 0.00 | -3.17m | 4.34m | -- | -- | -- | -- | -- | -0.0426 | -0.0426 | 0.00 | -0.0787 | 0.00 | -- | -- | -- | -338.26 | -402.58 | -- | -- | -- | -- | -- | -- | -- | -5.83 | -- | -- | -- | -- | 16.71 | -- | -- | -- |
| Entourage Health Corp | 39.46m | -116.92m | 4.59m | 251.00 | -- | -- | -- | 0.1162 | -0.3807 | -0.3807 | 0.1285 | -0.4215 | 0.4954 | 1.79 | 8.08 | -- | -146.79 | -46.15 | -- | -74.68 | 6.12 | -53.10 | -296.29 | -214.31 | 0.0992 | -1.13 | 6.15 | -- | -3.26 | 94.98 | -56.01 | -- | -13.82 | -- |
| Appili Therapeutics Inc | 1.15m | -5.34m | 4.83m | 8.00 | -- | -- | -- | 4.20 | -0.044 | -0.044 | 0.0095 | -0.0811 | 0.5047 | -- | 2.12 | -- | -234.31 | -117.41 | -- | -173.66 | -- | -- | -464.23 | -3,037.15 | -- | -5.32 | -- | -- | -75.97 | -- | 63.20 | -- | -43.04 | -- |
| StageZero Life Sciences Ltd | 4.10m | -17.17m | 4.90m | 40.00 | -- | -- | -- | 1.19 | -0.1619 | -0.1619 | 0.0379 | -0.1006 | 0.6717 | 22.87 | 48.05 | 102,522.70 | -281.22 | -135.76 | -- | -- | 0.3457 | -2.74 | -418.64 | -246.92 | 0.0329 | -14.74 | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Principal Technologies Inc | 581.16k | -1.52m | 4.91m | -- | -- | 6.07 | -- | 8.45 | -0.0657 | -0.0657 | 0.0257 | 0.0247 | 0.577 | -- | 3.71 | -- | -147.50 | -- | -286.94 | -- | 42.98 | -- | -255.65 | -- | -- | -59.80 | 0.0757 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
| Innovotech Inc | 1.09m | -211.07k | 5.05m | 16.00 | -- | 5.40 | -- | 4.63 | -0.0054 | -0.0054 | 0.028 | 0.0241 | 0.9361 | 8.58 | 4.37 | -- | -18.12 | 4.37 | -20.49 | 5.75 | 67.57 | 72.43 | -19.35 | 2.86 | 6.10 | -- | 0.00 | -- | -24.02 | 2.60 | -137.18 | -- | 39.25 | -- |
| Delta 9 Cannabis Inc | 71.07m | -17.52m | 5.21m | 200.00 | -- | -- | -- | 0.0733 | -0.0997 | -0.0997 | 0.4129 | -0.0342 | 0.8686 | 3.33 | 33.55 | 355,326.70 | -20.33 | -13.74 | -52.07 | -23.39 | 25.29 | 26.99 | -23.41 | -17.98 | 0.1337 | -4.69 | 1.11 | -- | 12.39 | 56.50 | 35.61 | -- | -48.22 | -- |
